The threat of influenza
1 / 95

- PowerPoint PPT Presentation

  • Updated On :

The Threat of Influenza. Damara Gebauer Sai Jahann Bonnie Hart. Influenza . Overview Molecular Biology Clinical Bioweaponization. Influenza Overview. Commonly called “the flu”. It is a highly contagious disease caused by the influenza virus.

Related searches for

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about '' - rusty

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
The threat of influenza l.jpg

The Threat of Influenza

Damara Gebauer

Sai Jahann

Bonnie Hart

Influenza l.jpg

  • Overview

  • Molecular Biology

  • Clinical

  • Bioweaponization

Influenza overview l.jpg
Influenza Overview

  • Commonly called “the flu”. It is a highly contagious disease caused by the influenza virus.

  • It is a disease of the respiratory system, namely the throat, nose and lungs.

  • Can affect people of all ages including healthy people and symptoms are seen suddenly.

Influenza overview4 l.jpg
Influenza Overview

  • People most susceptible are the elderly, small children and immuno-compromised, although anyone can develop complications.

  • Complications include pneumonia, bronchitis, nose and ear infection.

  • “Stomach Flu” Myth

  • No aspirin for children or teenagers

Influenza overview5 l.jpg
Influenza Overview

  • 10-20% of the US population come down with the flu each year.

  • ~36,000 Americans succumb to complications of the disease. 250,000 people die world wide.

  • Vaccines are the first line of defense.

  • Antiviral medication is also available

  • Viral receptor proteins are primary targets of vaccines and antivirals

  • Hemagglutinin (HA) and Neuraminidase (NA) are targeted viral proteins

Influenza strains l.jpg
Influenza Strains

  • Single negative-stranded RNA virus

  • 3 Types: A, B, C

Type a l.jpg
Type A influenza%20virus.jpg

Beware of type a l.jpg
Beware of Type A

  • 15 known HA subtypes: H1-H15

  • 9 known NA subtypes: N1-N9

  • While all subtypes can be found in birds, only H1-H3 and N1-N2 are known to circulate widely in humans.

  • H1-H3 are the only types known to have caused pandemics in humans

    • Pandemics arise from flu strains that have novel HA and NA proteins that people have no immunity to

Beware of type a10 l.jpg
Beware of Type A

  • New strains can form by genetic re-assortment between animal and human strains. 1956 (Asian) and 1968 (Hong Kong) were formed this way.

  • Recently been discovered that wholly avian strains CAN directly infect humans

  • Epidemic occurred in 1997 in Hong Kong. 18 people were infected and 6 died from complications.

Beware of type a11 l.jpg
Beware of Type A

  • Previously it was thought that humans could not be infected by wholly avian flu and that an intermediary step was required

  • Pigs were thought to be this intermediary step.

  • Avian or some other animal flu infected pigs, re-assortment occurs creating new strain which then has potential to infect humans.

  • 1997 Hong Kong incident showed pigs are not required to be intermediary step since re-assortment can occur directly in humans

Avian flu why such a threat l.jpg
Avian flu: Why such a threat?

  • HA and NA surface proteins are generally not recognized by human respiratory cells

  • Wholly avian flu infects humans at a low frequency but has huge pandemic potential.

  • 1997 Hong Kong incident was first case of wholly avian flu infecting humans. Fortunately, flu could not spread from person to person.

Avian flu why such a threat13 l.jpg
Avian flu: Why such a threat?

  • If avian strain were to spread from person to person, most of the population will have no prior immunity to the HA and NA proteins and a devastating pandemic could occur.

  • Also, if avian strain and common human strain infect host simultaneously, could get re-assortment and creation of a super influenza strain.

  • WHO and other organizations are watching Asia and other countries with avian flu outbreaks very closely

Three pandemics in 20 th century l.jpg
Three Pandemics in 20th Century

  • 1918 Spanish Influenza– A(H1N1)

  • 1957Asian Influenza—A(H2N2)

  • 1968 Hong Kong Influenza—A(H3N2)

Spanish 1918 pandemic l.jpg
Spanish 1918 Pandemic

Influenza A H1N1

Spanish influenza 1918 l.jpg
Spanish Influenza 1918

  • The most devastating flu pandemic the world had seen.

  • Named Spanish influenza because of the severe loss in Spain. 8 million people died in May 1918.

  • In the U.S, first signs were seen in early spring in military camps in Kansas, but received little attention because of the war in Europe.

Spanish influenza 191817 l.jpg
Spanish Influenza 1918

  • By the fall, hospitals were overwhelmed with patients, many of whom were dying 2-3 days after exhibiting symptoms.

  • The pandemic was extremely sudden. No one was prepared. In the US, the average life span was reduced by 10 years.

  • ~675,000 American deaths.

Spanish influenza 191818 l.jpg
Spanish Influenza 1918

  • 40 million people worldwide were dead from the flu.

  • Most striking was the high morbidity of young people (20-40 years old).

  • Influenza's full impact: millions of hospitalizations, secondary bacterial pneumonias, and middle ear infections in infants and young children.

  • Caused by H1N1 strain that resembled most closely swine origin.

1957 asian influenza a h2n2 l.jpg
1957 Asian Influenza—A(H2N2)

  • Re-assortment of avian and human strains.

  • Re-assortment thought to have occurred in pigs.

  • 70,000 deaths in America. First identified in China in February 1957, it spread to the US by June 1957

1968 hong kong influenza a h3n2 l.jpg
1968 Hong Kong Influenza—A(H3N2)

  • Also re-assortment of avian and human strains.

  • 34,000 deaths in America. Started in Hong Kong in early 1968 and spread to America by the end of the year.

  • A(H3N2) is still circulating in human population today.

Influenza today l.jpg
Influenza Today

  • Kills an average of 36,000 Americans every year and 250,000 around the world.

  • ~115,000 Americans are hospitalized for the flu each year

Recent news revenge of the birds l.jpg
Recent News: Revenge of the Birds

  • 1997 Hong Kong A(H5N1)- First reported case of direct transmission from bird to human.

  • 1999 Hong Kong A(H9N2)- 2 children infected with avian flu and transmission was believed to be direct bird to human. Both children recuperated.

  • 2003 Hong Kong A(H5N1)- a father and son traveling to mainland came down with flu, father did not survive. Source of infection remains unknown.

Recent news l.jpg
Recent News

  • 2003 Netherlands A(H7N7)- Outbreak of avian flu in farmed poultry. 80 poultry workers and their families became ill. There seemed to be some human to human transmission. One patient died.

  • 2003 Hong Kong A(H9N2)- One child became ill with avian flu but recovered.

  • Present day- Several Asian countries including China, Thailand, Vietnam, Indonesia and others are having outbreaks of avian flu among farmed poultry.

Influenza molecular biology l.jpg
Influenza: Molecular Biology

  • What differentiates influenza from other viruses?

  • How does an influenza virus particle interact with a host cell?

  • Why is it so contagious? So dangerous?

Characteristics of viruses l.jpg
Characteristics of viruses

  • Genome enclosed in protein shell

  • Can only reproduce within host cell

  • Each type of virus has specific “host range”

  • Reprogramming of cell

    • Copy viral genes

    • Manufacture viral proteins

Structure of influenza l.jpg
Structure of Influenza

  • Viral envelope

    • Surface studded with spikes

  • Matrix protein (M1)

  • 8 RNA segments

  • Non-structural proteins

    • Nuclear export protein (NEP)

    • NS1 protein

    • Nucleocapsid protein (NP)

    • Polymerase components

Surface proteins of influenza a b l.jpg
Surface proteins of influenza A/B

  • Hemagglutinin (HA)

    • Rod-shaped

    • Binds virus to host cell to initiate infection

    • Brings about fusion

    • 15 types

  • Neuraminidase (NA)

    • Mushroom-shaped

    • Prevents viral aggregation upon release

    • 9 types

Genome segments encoding l.jpg
Genome segments – encoding

  • 4: HA

  • 6: NA

  • 7: M1/M2 Matrix proteins

  • 5: Nucleoprotein (NP)

  • 1,2,3: Polymerase machinery (PB-2, PB-1, PA)

  • 8: Non-structural proteins: NS1, NEP

Genetic variation of influenza a l.jpg
Genetic variation of influenza A

  • Causes introduction of new, pandemic strains

  • Mutational frequency comparable to other viruses

    • Can’t be the only explanation

  • Unique ability to undergo antigenic variation

    • Antigen: interacts with cell and antibody

    • Antigenic drift: minor changes

    • Antigenic shift: major differences; new strains

Genetic variation antigenic drift l.jpg
Genetic Variation: Antigenic Drift

  • Accumulation of point mutations eventually result in amino acid substitutions

  • HA glycoprotein:

    • Results in differences in key antigenic sites at which the host antibody binds

    • Prevent binding of antibodies induced by previous infection

  • Also occurs in NA glycoprotein

Genetic variation antigenic shift l.jpg
Genetic Variation: Antigenic Shift

  • Involves replacement of entire gene segments

    • Results in novel viruses

  • Occurs suddenly in association with pandemics

  • Through dual infection: different influenza viruses infect a single cell

  • Does not occur in NA glycoprotein

Genetic variation antigenic shift33 l.jpg
Genetic Variation: Antigenic Shift

  • One cell is infected by two different influenza A viruses

    • Not necessarily human flu

  • Inside the cell, spontaneous self-assembly can produce recombinant viruses

  • Those viruses bud out of cell and infect other host cells

  • A new flu strain is born!

Infection cycle of influenza l.jpg
Infection cycle of influenza

  • Binding of virus to cell

  • Cell engulfs virus via endocytosis

  • Membrane of virus fuses with endosome; RNA released into cell

  • Viral polymerase produces mRNA from viral RNA

  • Protein, new RNA produced

  • Self-assembly produces virions

  • Virions bud off cell membrane

Infection cycle binding and endocytosis l.jpg
Infection cycle: Binding and endocytosis

  • HA contains receptor binding site for virus

    • Binds to sialic acid residue on cell surface glycoprotein

  • Binding triggers receptor-mediated endocytosis

    • Virus is taken into endosome

    • Low pH of endosome causes fusion of viral and endosome membranes

Infection cycle endocytosis and membrane fusion l.jpg
Infection cycle:Endocytosis and membrane fusion

Infection cycle fusion of viral and cell membranes l.jpg
Infection cycle:Fusion of viral and cell membranes

  • Cleavage of HA is necessary

    • This allows fusion of membranes

  • HA cleaved at arginine in cleavage site

  • More arginines = more proteases cleaving

    • Mutated viruses can be cleaved by more proteases

  • Virus is more infective

    • More of the cells it attaches to will get exposed to viral genome.

Infection cycle viral replication l.jpg
Infection cycle:Viral replication

  • Negative-sense viral RNA is transcribed to mRNA by viral polymerase (PB1, PB2, PA)

    • mRNA complements made for incorporation into new virions

    • mRNA translated to produce viral proteins

      • For incorporation into virions

      • For use in infected cell (NEP, NS1)

Infection cycle viral budding l.jpg
Infection cycle:Viral budding

  • HA and NA incorporated into host cell membrane

  • M1 matrix protein forms shell, bound to:

    • Cytoplasmic tails of HA, NA

    • Viral ribonucleoproteins

    • Other M1 molecules

  • Virus buds off via exocytosis

Host cell v influenza a virus l.jpg
Host cell v. influenza A virus

  • Human cell has initial antiviral defenses

    • Interferon-α/β-independent response

    • Protein kinase R

    • Interferon-α/β response

  • Virus needs to counteract these to reproduce

    • NS1A protein

Host cell v influenza a virus41 l.jpg
Host cell v. influenza A virus

  • Interferon-α/β-independent protection

    • Upon infection by virus, activate transcription factors that control expression of antiviral genes

      • Interferon regulatory factor-3 (IRF-3), IRF-7

      • Combine with coactivators to form virus-activated factor (VAF)

      • VAF induces transcription of genes that code for antiviral proteins

Host cell v influenza a virus42 l.jpg
Host cell v. influenza A virus

  • Protein Kinase-R (PKR) protection

    • Activated by presence of double-stranded RNA

      • Consequence of RNA virus presence in cell

    • Activated PKR inhibits protein synthesis and therefore viral replication

      • Phosphorylates translation initiation factor eIF2

Host cell v influenza a virus43 l.jpg
Host cell v. influenza A virus

  • Interferon-α/β response

    • Infected cell produces IFN-α/β

      • Signal travels to neighboring uninfected cells

    • In infected and neighboring cells, induces transcription of antiviral proteins

      • Protects infected cell against current infection

      • Prepares at-risk cells to withstand infection

    • Induces production of MxA protein

      • Largely responsible for inhibition of influenza A

Host cell v influenza a virus44 l.jpg
Host cell v. influenza A virus

  • Influenza NS1A protein inhibits 3’-end processing of cell mRNA

    • Prevents addition of poly-A tail

    • Doesn’t affect viral mRNA processing

  • Inhibits activation of PKR

    • Mechanism not clearly understood

  • Enough IFN-β produced to protect neighboring cells

Influenza effect on host cells l.jpg
Influenza effect on host cells

  • Turns off protein function

    • NS1A protein

  • Causes cell death

    • Induces apoptosis

    • Dead cells shed off respiratory tract lining

    • Can cause shedding down to basement membrane layer

  • Infects respiratory tract; causes clinical symptoms

Influenza virus types l.jpg
Influenza Virus Types

  • Type A

    • humans and other animals

    • all age groups

    • moderate to severe illness

  • Type B

    • milder epidemics

    • humans only

    • primarily affects children

  • Type C - uncommon strain, no epidemic

Common flu symptoms l.jpg
Common Flu Symptoms

  • High Fever

  • Headache

  • Extreme-tiredness/weakness

  • Dry cough

  • Sore throat

  • Stuffy/runny nose

  • Muscle aches

  • Diarrhea and vomiting

Cold v flu l.jpg
Cold v. Flu

  • Flu is worse than common cold

  • Symptoms more intense in flu (fever, body aches, tiredness, and dry cough)

  • Colds- more likely to have runny or stuffy nose

  • Colds don’t result in serious health problems (pneumonia, bacterial infections, or hospitalizations)

Increased risk l.jpg
Increased Risk

  • Age 65 and older

  • Any age with chronic medical conditions

  • Pregnant women

  • Children 6-23 months

Emergency warning signs in children l.jpg
Emergency Warning Signs- In children

  • High or prolonged fever

  • Fast breathing or trouble breathing

  • Bluish skin color

  • Not drinking enough fluids

  • Changes in mental status

  • Flu-like symptoms improve but then return

  • Worsening of underlying chronic medical conditions

Emergency warning signs in adults l.jpg
Emergency Warning Signs- In adults

  • High or prolonged fever

  • Difficulty breathing or shortness of breath

  • Pain or pressure in chest

  • Near-fainting or fainting

  • Confusion

  • Severe or persistent vomiting

Spread of flu l.jpg
Spread of Flu

  • Droplet Spread

    • from a person’s cough or sneeze

    • person touches respiratory droplets on another person or object and then touches their own mouth or nose

  • Incubation period = 1-4 days (avg. = 2 days)

  • Adults infectious from day before symptoms begin to 5 days after illness onset

  • Children- infectious for > 10 days

Symptoms l.jpg

  • Adults- shed virus 1 day before developing symptoms to 7 days after getting sick

  • Young children- can shed virus for longer than 7 days

Complications l.jpg

  • Bacterial pneumonia

  • Dehydration

  • Worsening chronic conditions

    • congestive heart failure

    • asthma

    • diabetes

  • Children can develop sinus problems and ear infections

Complications cont l.jpg

  • Lead to pulmonary or cardiac disease

  • Lead to 2ndary bacterial pneumonia or primary influenza viral pneumonia

  • Children

    • 20% hospitalized can have febrile seizures

  • Influenza is associated w/ encephalopathy, transverse myelitis, Reye syndrome, myositis, myocarditis, and pericarditis

Hospitalization from influenza l.jpg
Hospitalization from Influenza

  • Highest rate among young children and persons >65 yrs

  • 1969-70 through 1994-95 influenza epidemic: 16,000-220,000 hosp./epidemic

  • 114,000 hospitalizations/yr with 57% occurring in ages < 65 yrs

  • Highest # caused by type A (H3N2) viruses

Deaths l.jpg

  • Result from pneumonia and/or worsening of cardiopulmonary conditions and other chronic diseases

  • 5th leading cause of death for adults > 65

  • 1976-90 epidemic  19,000 deaths

  • 1990-99 epidemic  36,000 deaths

  • In 23 epidemics (‘72-’95): 20,000 excess deaths in 11 epidemics and 40,000 deaths in 6 epidemics

Death rates from influenza associated pulmonary and circulation deaths 100 000 persons l.jpg
Death rates from influenza-associated pulmonary and circulation deaths/100,000 persons

  • 0-44 yr: 0.4 - 0.6

  • 50-64yr: 7.5

  •  65yrs: 98.3

  • Reasons:

    • more older people has inc.

    • Influenza A associated with higher mortality

    • Influenza A predominates in 90% of seasons from 1990-99 compared w/57% of seasons 1976-90

Laboratory diagnosis l.jpg
Laboratory Diagnosis circulation deaths/100,000 persons

  • Can determine circulating types, subtypes, and strains

  • Tests include

    • viral culture

    • serology

    • rapid antigen testing

    • PCR

    • immunofluorescence

Commercial rapid diagnosis tests l.jpg
Commercial rapid diagnosis tests circulation deaths/100,000 persons

  • Detect viruses in 30 minutes

  • Specimens used are either throat swabs, nasal wash or nasal swab

  • Sensitivity of rapid tests are lower than that of viral cultures  confirm (-) tests with viral culture

  • Does not provide specific info on circulating subtypes and strains

Preventing the flu l.jpg
Preventing the Flu circulation deaths/100,000 persons

  • Good Health Habits

  • Vaccination

  • Antiviral Medications

Good health habits l.jpg

Avoid close contact circulation deaths/100,000 persons

Stay home when you are sick

Cover your mouth

Clean your hand

Avoid touching your eyes, nose or mouth

Get plenty of rest

Drink plenty of liquids

The simplest way to avoid the flu is to avoid crowds. Can’t keep you kids cooped up? Frequent hand washing is the next best thing

Good Health Habits

Vaccination l.jpg
Vaccination circulation deaths/100,000 persons

Vaccination68 l.jpg
Vaccination circulation deaths/100,000 persons

  • Best way to prevent flu

  • Selection of virus for manufactured vaccine made in Feb and April each year

  • Get vaccinated each fall

  • People at high risk should get vaccinated

  • 2 kinds of vaccines

    • inactivated

    • live attenuates (LAIV) (for ages 5 - 49)

Who should not get vaccine l.jpg
Who Should Not Get Vaccine circulation deaths/100,000 persons

  • Have severe allergy to hen’s eggs (anaphylactic allergic rxn)

  • People who previously developed Guillian-Barre syndrome (GBS) w/in 6 weeks after getting a flu shot

Live attentuated intranasal influenza laiv l.jpg
Live Attentuated Intranasal Influenza (LAIV) circulation deaths/100,000 persons

  • Contains weakened live influenza vs killed viruses

  • Administered by nasal spray

  • Contains 3 different live (but weakened) viruses, which stimulate body to make antibodies

Live attentuated intranasal influenza laiv71 l.jpg
Live Attentuated Intranasal Influenza (LAIV) circulation deaths/100,000 persons

  • Attenuated, producing mild or no signs or symptoms

  • Temperature-sensitive-limits the replication of vaccine viruses at 38-39°C  restricts LAIV viruses from replicating efficiently in human lower airways

  • Cold-adapted, replicating efficiently at 25°C  restrictive for replication of different wild-type viruses

Dosage laiv l.jpg
Dosage-LAIV circulation deaths/100,000 persons

  • 0.5 mL of vaccine: 0.25 mL for each nostril

  • Children aged 5-8 previously unvaccinated: receive 2 doses separated by 6-10 weeks

  • Children aged 5-8 previously vaccinated: receive 1 dose (do not require a 2nd dose)

  • Persons aged 9-49: receive 1 dose

Efficacy effectiveness of laiv children l.jpg
Efficacy & Effectiveness of LAIV-children circulation deaths/100,000 persons

  • Season 1:

    • 93% efficiency for those who received 2 doses

    • 91% for those those who received 1 dose

  • Season 2:

    • 86% overall efficiency

    • A (H2N2) component of vaccine was not well matched for circulating virus strains

Efficacy effectiveness of laiv adults l.jpg
Efficacy & Effectiveness of LAIV-adults circulation deaths/100,000 persons

  • 85% overall efficiency

  • Vaccination reduced severe febrile illnesses by 19% and upper respiratory tract illnesses by 24%

  • Fewer days of illness

  • 15-42% fewer health care provider visits

  • 43-47% less use of antibiotics

Liav side effects l.jpg

Children circulation deaths/100,000 persons

runny nose



muscle aches



runny nose


sore throat



LIAV Side Effects

Inactivated influenza vaccine l.jpg
Inactivated Influenza Vaccine circulation deaths/100,000 persons

  • Contains two type A and one type B

  • Made from purified, egg grown viruses that have been inactivated or killed

  • Antibiotics can be added to prevent bacterial contamination

  • Vaccinated people develop high postvaccination hemagglutination inhibition antibody titers

Dosage inactivated l.jpg
Dosage-Inactivated circulation deaths/100,000 persons

  • 15g/dose of H1N1 virus and H3N2 type A virus plus a type B strain

  • Children previously unvaccinated: 2 doses one month apart (2nd dose should be administered before December)

  • Vaccinated in the deltoid muscle ( needle length > 1 inch in order to penetrate muscle tissue in adults;7/8-1 inch for children)

  • Infants should be vaccinated in the anterolateral aspect of the thigh

Effectiveness of inactivated vaccine children l.jpg
Effectiveness of Inactivated Vaccine- Children circulation deaths/100,000 persons

  • 77% - 91% effective against influenza respiratory illness

  • Effective against influenza seroconversion:

    • age 1-5  44- 49%

    • age 6-10  74-76%

    • age 11-15  70- 80%

  • Another study: > 89% overall efficiency for 6-24 months old

Effectiveness of inactivated vaccine adults l.jpg
Effectiveness of Inactivated Vaccine-Adults circulation deaths/100,000 persons

  • Aged < 65 yrs old:

    • 70-90% efficient

    •  work absenteeism,  health-care resources

  • Aged > 65 yrs old:

    • 50-60% effective in preventing hospitalization for pneumonia and influenza

    • 80% effective in preventing death

Side effects to inactivated vaccine l.jpg
Side Effects to Inactivated Vaccine circulation deaths/100,000 persons

  • Soreness at vaccination site

  • Fever, malaise, myalgia

  • Guillain Barre Syndrome: 1 additional case per 1 million people

    • Body's immune system attacks part of the nervous system and results in weakness or tingling sensations in the legs that can spread to the arms and upper body.

    • Can result in paralysis

Inactivated v live vaccines l.jpg

Similarities circulation deaths/100,000 persons

contain one influenza A (H3N2) virus, one A (H1N1) virus, and one B virus

vaccines grown in eggs

administered annually


Inactivated has killed virus, LAIV contains attentuated viruses

Cost: LAIV more expensive

who gets what vaccine


LAIV: intranasally

dead: intermuscularly

Inactivated v. Live Vaccines

Antiviral medications l.jpg
Antiviral Medications circulation deaths/100,000 persons

  • 4 medications:

    • Amantadine: orally administered, treats type A

    • Rimantadine: orally administered, treats type A only for adults

    • Oseltamivir-capsule, treats type A & type B

    • Zanamiv-inhaled powered drug, treats type A& type B

  • Last for 5 days and must be started w/in the 1st 2 days of illness

  • Used to control outbreaks in institutions

Antiviral medications83 l.jpg
Antiviral Medications circulation deaths/100,000 persons

  • Drugs are 70-90% effective for prevention

  • If taken w/in 2 days of getting sick, drugs reduce symptoms and shorten time of sickness by 1-2 days

  • Have side effects

Amantadine and rimantadine side effects l.jpg
Amantadine and Rimantadine Side Effects circulation deaths/100,000 persons

  • CNS side effects: nervousness, anxiety, difficulty concentrating, light headedness (occur more often w/amantadine)

  • Gastrointestinal side effects: nausea, loss of appetite

  • People w/ long-term illnesses: delirium, hallucinations, agitation, and seizures

  • Side effects disappear after 1 week

Zanamivir side effects l.jpg
Zanamivir Side Effects circulation deaths/100,000 persons

  • Drug is inhaled and can effect those w/asthma or other chronic lung diseases

  • Decreased respiratory function, bronchospasm

  • Less than 5% reported diarrhea, nausea, sinusitis, nasal infection, bronchitis, cough, headache, and dizziness

Oseltamivir side effects l.jpg
Oseltamivir Side Effects circulation deaths/100,000 persons

  • Gastrointestinal side effects

    • nausea

    • vomiting

  • Less severe if taken with food

Economics l.jpg
Economics circulation deaths/100,000 persons

  • Annual direct medical cost = $4.6 billion

  • Total direct and indirect costs = $12 billion (indirect includes work days lost, school days lost, etc.)

  • Vaccination can reduce these costs from hospitalizations, lost work days and antibiotic use.

Is a pandemic imminent l.jpg
Is a pandemic imminent? circulation deaths/100,000 persons

  • Experts (WHO, CDC) are saying yes.

  • It will occur as a natural disaster or as a bio-terrorist attack.

  • Either way we are not ready to respond to a flu pandemic

Influenza as a bioweapon l.jpg
Influenza as a Bioweapon? circulation deaths/100,000 persons

  • Suicide bio-bomber:a terrorist infects himself with super flu (e.g. avian and human influenza cross), spreads infection.

  • Now possible to make infectious flu virus from cloned DNA of the 8 RNA segments. This could bring back the 1918 Spanish Influenza.

  • Genetically modify avian flu strain so that can recognize human hosts’ receptors. This could be deadly.

Bioweapon pros l.jpg
Bioweapon Pros circulation deaths/100,000 persons

  • Highly contagious

  • Difficult to contain people (as opposed to animals)

  • Hard to determine strain for vaccine defense

  • Mostly likely will not have appropriate vaccine(s) at time of attack.

  • Relatively easy to obtain.

Bioweapon pros91 l.jpg
Bioweapon Pros circulation deaths/100,000 persons

  • Infect farmed poultry and damage poultry industry and the US economically.

  • Flu strain need not be lethal since it’s so contagious already. If infect enough people can cause social and economic strain by wiping out work force.

  • First cluster of cases would probably not alert officials. This could give pandemic head start.

  • Difficult to eradicate because of bird and other animal reservoirs.

Bioweapon pros92 l.jpg
Bioweapon Pros circulation deaths/100,000 persons

  • Greater threat to world leaders because they are generally older and more susceptible to the virus.

Bioweapon cons l.jpg
Bioweapon Cons circulation deaths/100,000 persons

  • Strain may not be lethal, people could recuperate

  • So far, wholly avian strain can not get human to human transmission. This would not be contagious.

  • Highly unlikely that terrorists would have expertise to conduct recombinant DNA technology research or have the resources.

Lines of defense l.jpg
Lines of Defense circulation deaths/100,000 persons

  • Stockpiles of vaccines, may have to replenish to account for strain shifts

  • Increase security and monitor laboratories conducting influenza research and manufacturers that are distributing vaccines and antivirals.

  • Healthcare workers should increase immunization for people who need it now.

  • Equip healthcare workers and possibly pharmacies with proper flu assay kits so they can identify disease quickly.

Therefore beware l.jpg
Therefore, Beware! circulation deaths/100,000 persons

  • Influenza is more than “just a cold”

  • A pandemic can have drastic social, economic, and health consequences

  • Influenza is a potential and effective bioweapon that we should be prepared to see